Reduction of bone marrow dose by intensity-modulated radiotherapy for patients with cervical cancer after hysterectomy
Hui-ling LI,Jian-ji PAN,Peng-gang BAI,Bin ZHANG,Cedric YU
DOI: https://doi.org/10.3760/cma.j.issn.1004-4221.2009.03.221
2009-01-01
Abstract:Objective To compare whole pelvic conventional radiotherapy (CRT) and intensity-modulated radiotherapy(IMRT) techniques in reducing the volume and dose of bone marrow of patients with cervical cancer after hysterectomy. Methods Seventeen patients with stage ⅠA-ⅡB cervical cancer after hysterectomy were selected. Clinical tumor volume(CTV) included parametria, presacral space, upper vagi-na,pelvic and common iliac lymph nodes. Planning tumor volume(PTV) was 1 cm extention of the CTV. The Pinnacle planning system version 7.4f was used to develop conventional and Seven-field IMRT plans,re-spectively. Conventional treatment planning included AP/PA fields(CRT2f) and four-field(CRT4f). The pre-scribed dose was 45.0 Gy and 50.4 Gy, respectively. All plans were optimized to assure that more than 97% of PIN volume received 95% of prescribed dose. The dose volume histograms were used to compare V20, V25, V30 and V40 of the bone marrow among different plans. Results On 45.0 Gy prescription, the V25, V<,30>or V40 of the right and left ilium bone marrow were 45.04% and 40.90%, 64.37% and 65.25%, 60.20% and 61.42% (H=7.45,P=0.024 and H=6.62,P=0.038) in IMRT7f, with 36.91% and 22.21%, 52.69% and 48.80%, 40.52% and 42.33% (H=7.91,P=0.019 and H=10.5,P=0.005) in CRT2f, 23.83% and 19.65%,51.85% and46.11%,37.97% and 35. 30% (H=17.14, P=0.000 and H=20.71,P=0.000)in CRT4f;on 50.4 Gy prescription,with 52.43% and 50.06%, 65.89% and 67.75%, 69.56% and 64.23% (H=6.29,P=0.043 and H=6.37,P=0.041) in IMRT7f,38.91% and 31.93%, 54.96% and 51.29% ,52.18% and 47.57% (H=6.91, P=0.031 and H=15.19,P=0.000) in CRT2f,25.93% and 20.87%, 53.30% and 49.83%, 44.26% and 37.77% (H=16.71, P=0.000 and H=20.78, P=0.000) in CRT4f. Conclusions Compared with CRT, IMRT can guarantee better target dose distribution, less irradiation volume and lower dose of bone marrow in cervical cancer after hysterectomy.